ADVISORY, March 27, 2017 (GLOBE NEWSWIRE) --
What:
Aduro Biotech, Inc. (Nasdaq:ADRO), an immunotherapy company focused on the discovery, development and
commercialization of therapies that transform the treatment of challenging diseases, will visit the Nasdaq MarketSite in Times
Square.
In honor of the occasion, Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, and members of
the Aduro management team, will ring the Opening Bell.
Where:
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
When:
Tuesday, March 28, 2017 – 9:15 a.m. to 9:30 a.m. ET
Aduro Biotech Media Contact:
Susan Lehner
510 809 2137
slehner@aduro.com
Nasdaq MarketSite:
Emily Pan
(646) 441-5120
emily.pan@nasdaq.com
Feed Information:
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK
Social Media:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please
visit our Facebook page:
http://www.facebook.com/NASDAQ
For photos from ceremonies and events, please visit our Instagram page:
http://instagram.com/nasdaq
For livestream of ceremonies and events, please visit our YouTube page:
http://www.youtube.com/nasdaq/live
For news tweets, please visit our Twitter page:
http://twitter.com/nasdaq
For exciting viral content and ceremony photos, please visit our Tumblr page:
http://nasdaq.tumblr.com/
Webcast:
A live stream of the Nasdaq Opening Bell will be available at:
https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos:
To obtain a hi-resolution photograph of the Market Open, please go to http://business.nasdaq.com/discover/market-bell-ceremonies and click on the market open of your
choice.
About Aduro
Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of
therapies that transform the treatment of challenging diseases. Aduro's technology platforms, which are designed to harness the
body's natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and
infectious diseases. Aduro's LADD technology platform is based on proprietary attenuated strains of Listeria that have been
engineered to express tumor-associated antigens to induce specific and targeted immune responses. This platform is being developed
as a treatment for multiple indications, including mesothelioma, ovarian, lung and prostate cancers. Additionally, a personalized
form of LADD, or pLADD, is being developed utilizing tumor neoantigens that are specific to an individual patient’s tumor. Aduro's
STING Pathway Activator platform is designed to activate the STING receptor in immune cells, resulting in a potent tumor-specific
immune response. ADU-S100 is the first STING Pathway Activator compound to enter the clinic and is currently being evaluated in a
Phase 1 study in patients with cutaneously accessible metastatic solid tumors or lymphomas. Aduro’s B-select monoclonal antibody
platform includes a number of immune modulating assets in research and preclinical development. Aduro is collaborating with leading
global pharmaceutical companies to expand its products and technology platforms. For more information, please visit www.aduro.com.
About Nasdaq
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public
company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables clients to plan, optimize and
execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating
today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than
85 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 3,800 listed
companies with a market value of $10.1 trillion and nearly 18,000 corporate clients. To learn more, visit: business.nasdaq.com.
-NDAQA-
